Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Vella, A; Bock, G; Giesler, PD; Burton, DB; Serra, DB; Saylan, ML; Deacon, CF; Foley, JE; Rizza, RA; Camilleri, M.
The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
Clin Endocrinol (Oxf). 2008; 69(5):737-744
Doi: 10.1111/j.1365-2265.2008.03235.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Treiber Gerlies
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objectives The incretin hormone glucagon-like peptide-1 (GLP-1) retards gastric emptying and decreases caloric intake. It is unclear whether increased GLP-1 concentrations achieved by inhibition of the inactivating enzyme dipeptidyl peptidase-4 (DPP-4) alter gastric volumes and satiation in people with type 2 diabetes. Methods In a double-blind, placebo-controlled crossover design, 14 subjects with type 2 diabetes received vildagliptin (50 mg bid) or placebo for 10 days in random order separated by a 2-week washout. On day 7, fasting and postmeal gastric volumes were measured by a (99m)Tc single-photon emission computed tomography (SPECT) method. On day 8, a liquid Ensure (R) meal was consumed at 30 ml/min, and maximum tolerated volume (MTV) and symptoms 30 min later were measured using a visual analogue scale (VAS) to assess effects on satiation. On day 10, subjects ingested water until maximum satiation was achieved. The volume ingested was recorded and symptoms similarly measured using a VAS. Results Vildagliptin raised plasma GLP-1 concentrations. However, fasting (248 +/- 21 vs. 247 +/- 19 ml, P = 0.98) and fed (746 +/- 28 vs. 772 +/- 26 ml, P = 0.54) gastric volumes did not differ when subjects received vildagliptin or placebo. Treatment with vildagliptin did not alter the MTV of Ensure (R) (1657 +/- 308 vs. 1389 +/- 197 ml, P = 0.15) or water compared to placebo (1371 +/- 141 vs. 1172 +/- 156 ml, P = 0.23). Vildagliptin was associated with decreased peptide YY (PYY) concentrations 60 min after initiation of the meal (166 +/- 27 vs. 229 +/- 34 pmol/l, P = 0.01). Conclusions Vildagliptin does not alter satiation or gastric volume in people with type 2 diabetes despite elevated GLP-1 concentrations. Compensatory changes in enteroendocrine secretion could account for the lack of gastrointestinal symptoms.
- Find related publications in this database (using NLM MeSH Indexing)
- Adamantane - analogs and derivatives
- Cross-Over Studies -
- Diabetes Mellitus, Type 2 - metabolism
- Dipeptidyl-Peptidase IV Inhibitors - pharmacology
- Double-Blind Method -
- Drinking - physiology
- Eating - physiology
- Enteroendocrine Cells - drug effects
- Fasting - blood
- Gastric Emptying - drug effects
- Ghrelin - blood
- Glucagon-Like Peptide 1 - blood
- Humans -
- Hypoglycemic Agents - pharmacology
- Middle Aged -
- Nitriles - pharmacology
- Organ Size - drug effects
- Placebos -
- Postprandial Period - drug effects
- Pyrrolidines - pharmacology
- Satiation - drug effects
- Stomach - drug effects